LEXICON
No.82 September 19, 2011

(New drug application (NDA)) Review report
審査報告書
Report on the deliberation results
審議結果報告書
Clinical trial (study) report
治験総括報告書
Summary technical documentation (STED)
申請資料概要
Application for marketing approval; new drug application (NDA)
製造販売承認申請書
Application dossier
申請資料
Summary basis of approval (SBA)
新医薬品承認審査概要

New drug application (NDA) review reports (審査報告書) are extensive reports that outline the NDA review process and conclusion for each new drug approved in Japan. Review reports are prepared by the Pharmaceuticals and Medical Devices Agency (PMDA; 医薬品医療機器総合機構) and published...

To read the full story

LEXICON

By Philip Carrigan

The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…

By Takashi Ebisawa

Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

By Ken Yoshino

Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…

For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…